Skip to main content

Table 3 Clinical performance of current screening methods and models for screening cohorts at baseline (CIN2+)

From: Development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in China

   Sensitivity
% (95% CI)
Specificity
% (95% CI)
AUC
(95% CI)
Referral rate
% (95% CI)
Screening cohort I (N = 3179)     
HPV hrHPV mRNA 97.44 (93.59–100.00) 85.94 (84.65–87.20) 0.92 (0.90–0.94) 16.14 (14.87–17.46)
Senior cytologists ASC-US 87.18 (79.49–93.59) 91.45 (90.52–92.39) 0.89 (0.86–0.93) 10.47 (9.43–11.59)
Co-testing 100.00 81.39 (80.01–82.75) 0.91 (0.90–0.91) 20.64 (19.24–22.08)
Base model 100.00 84.49 (83.23–85.75) 0.92 (0.92–0.93) 17.55 (16.24–18.92)
Base model + E6 93.59 (87.18–98.72) 92.26 (91.29–93.20) 0.93 (0.90–0.96) 9.81 (8.80–10.90)
Base model + GT 97.44 (93.59–100.00) 89.39 (88.26–90.42) 0.93 (0.92–0.95) 12.77 (11.63–13.98)
Base model + E6 + GT 97.44 (93.59–100.00) 89.04 (87.91–90.07) 0.93 (0.91–0.95) 13.09 (11.93–14.31)
Junior cytologists ASC-US 85.90 (78.21–93.59) 87.39 (86.20–88.55) 0.87 (0.83–0.91) 14.38 (13.17–15.64)
Co-testing 100.00 77.91 (76.46–79.26) 0.89 (0.88–0.90) 24.03 (22.56–25.56)
Base model 100.00 83.49 (82.20–84.78) 0.92 (0.91–0.92) 18.56 (17.22–19.96)
Base model + E6 91.03 (84.62–96.19) 91.97 (91.04–92.94) 0.92 (0.88–0.95) 10.07 (9.04–11.16)
Base model + GT 96.15 (91.03–100.00) 88.39 (87.23–89.49) 0.92 (0.90–0.94) 13.68 (12.51–14.93)
Base model + E6 + GT 96.15 (91.03–100.00) 87.81 (86.62–88.94) 0.92 (0.90–0.94) 14.22 (13.02–15.48)
Screening cohort II (N = 3082)     
HPV hrHPV DNA 90.20 (82.30–98.04) 84.16 (82.88–85.42) 0.87 (0.83–0.91) 17.07 (15.75–18.44)
Senior cytologists ASC-US 96.08 (90.20–100.00) 83.90 (82.55–85.19) 0.90 (0.87–0.93) 17.46 (16.13–18.84)
Co-testing 100.00 74.40 (72.81–76.01) 0.87 (0.86–0.88) 26.83 (25.28–28.44)
Base model 94.12 (86.27–100.00) 94.06 (93.20–94.89) 0.94 (0.91–0.97) 7.40 (6.50–8.38)
Base model + GT 96.08 (90.20–100.00) 95.17 (94.34–95.93) 0.96 (0.93–0.98) 6.33 (5.49–7.25)
Junior cytologists ASC-US 90.20 (80.39–98.04) 80.53 (79.18–81.95) 0.85 (0.81–0.90) 20.64 (19.22–22.11)
Co-testing 98.04 (94.12–100.00) 71.16 (69.55–72.75) 0.85 (0.83–0.87) 29.98 (28.37–31.63)
Base model 88.24 (78.43–96.08) 90.76 (89.74–91.82) 0.90 (0.85–0.94) 10.55 (9.48–11.68)
Base Model+GT 98.04 (94.12–100.00) 89.64 (88.55–90.70) 0.94 (0.92–0.96) 11.78 (10.66–12.97)
  1. AUC area under the curve, E6 E6 oncoprotein, GT HPV genotyping